NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on January 15, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, CA.
In addition to the presentation, the management team will engage in investor meetings throughout the conference. Interested parties can access the presentation through a live webcast, and a replay will remain available for two weeks following the event on the Events section of NeuroPace's Investor website.
Positive
- None.
Negative
- None.
News Market Reaction – NPCE
On the day this news was published, NPCE gained 4.70%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference at 4:30pm PT (7:30pm ET) on Wednesday, January 15, 2025, in San Francisco, CA. Management will also host investor meetings during the conference.
The presentation will be accessible via live webcast here. A webcast replay will be available for two weeks following the presentation in the Events section of NeuroPace’s Investor website at https://investors.neuropace.com.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When is NeuroPace (NPCE) presenting at the JP Morgan Healthcare Conference 2025?
How can investors watch NeuroPace's presentation at the JP Morgan Healthcare Conference?
Will NeuroPace (NPCE) management be available for investor meetings at the conference?
How long will the replay of NeuroPace's JP Morgan Conference presentation be available?
